Company news
Sera Prognostics, Inc. (NASDAQ:SERA) news
Sera Prognostics, Inc. news releases on 6ix. Latest, May 25, 2023: Sera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market…
Press releases — page 2
Sera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and Revenue
May 24, 2023
Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO
May 14, 2023
SERA PROGNOSTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
May 9, 2023
Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2023 Financial Results on May 10, 2023
April 26, 2023
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS
March 21, 2023
Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2022 Financial Results on March 22, 2023
March 8, 2023
Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL
February 14, 2023
SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA PREDICTING CLINICAL UTILITY AND COST EFFECTIVENESS OF THE PRETRM® TEST-AND-TREAT STRATEGY ACROSS DIVERSE POPULATIONS
November 14, 2022
SERA PROGNOSTICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
November 8, 2022
Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2022 Financial Results on November 9
October 26, 2022
SERA PROGNOSTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
August 9, 2022
Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2022 Financial Results on August 10
July 27, 2022
SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING IMPROVED PERFORMANCE OF ITS PRETRM® TEST WITH MORE PRECISE GESTATIONAL AGE
May 18, 2022
SERA PROGNOSTICS PRESENTS DATA DEMONSTRATING THE HEALTH AND ECONOMIC BENEFIT OF PRETRM® TESTING AT ISPOR ANNUAL MEETING
May 17, 2022
SERA PROGNOSTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS
May 9, 2022
SERA PROGNOSTICS AND NEWBORN FOUNDATION PARTNER TO REDUCE RISKS ASSOCIATED WITH PRETERM BIRTH AND IMPROVE HEALTH EQUITY THROUGH THE "EVERY MOTHER, EVERY BABY" PROJECT
May 4, 2022
Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2022 Financial Results on May 10
May 1, 2022
SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD
April 11, 2022
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2021 FINANCIAL RESULTS
March 28, 2022
Sera Prognostics Presents Data Demonstrating Prediction of Preeclampsia Utilizing Protein Biomarker and Clinical Factors at SRI Annual Meeting
March 17, 2022
Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2021 Financial Results on March 29
March 17, 2022
SERA PROGNOSTICS PRESENTATION RESCHEDULED FOR CITI 2022 HEALTHCARE CONFERENCE
February 16, 2022
SERA PROGNOSTICS ANNOUNCES NEW AGREEMENT WITH MULTIPLAN, EXPANDING PATIENT ACCESS TO THE PRETRM® TEST
January 31, 2022
SERA PROGNOSTICS ADDED TO NASDAQ BIOTECHNOLOGY INDEX
December 14, 2021
Sera Prognostics Announces Pricing For PreTRM® Test, The Only Broadly Validated Blood Test To Assess Risk Of Preterm Birth
December 1, 2021
Sera Prognostics Announces Publication Of Data Confirming The Performance Of The IBP4/SHBG Biomarkers In Diverse Non-U.S. Populations
November 30, 2021
Sera Prognostics Announces The Appointment Of Sandra A.J. Lawrence To The Sera Prognostics Board
November 29, 2021
Sera Prognostics Reports Third Quarter 2021 Financial Results
November 8, 2021
Sera Prognostics Announces The Appointment Of Zhenya Lindgardt To The Board
November 7, 2021
Sera Prognostics Appoints Woodrow Myers, MD, MBA As Advisor Of Public And Political Affairs
November 3, 2021
Sera Prognostics Announces Publication of the Clinical Validation of PreTRM® Threshold for Clinical Action
November 2, 2021
Sera Prognostics Announces Collaboration To Help Underserved Communities Make Informed Decisions About Prenatal Health
November 1, 2021
Sera Prognostics Announces Conference Call and Webcast of Third Quarter 2021 Financial Results on November 9
October 26, 2021
Sera Prognostics Appoints Dr. Paul Kearney as Chief Data Officer
September 27, 2021
Sera Prognostics to be Added to Russell 2000 Index
September 19, 2021
Sera Prognostics Appoints Dr. Michael R. Foley as Chief Medical Officer
September 14, 2021
Sera Prognostics Announces Publication of Health Economic Analysis Supporting PreTRM® Test-and-Treat Strategy to Improve Maternal and Infant Health
September 13, 2021
Sera Prognostics Reports Second Quarter 2021 Financial Results
August 29, 2021
Sera Prognostics’ PreTRM® Test and Treat Strategy Benefits Demonstrated by Results of Prospective, Randomized Controlled Intervention Trial Evaluating Clinical Utility
August 16, 2021
Sera Prognostics Announces Pricing of Initial Public Offering
July 13, 2021